Strategic Partnerships Terran already secures worldwide licensing deals and academic collaborations (Pierre Fabre, Sanofi, Columbia University/RFMH), signaling strong monetization potential through new licensing or co-development agreements for CNS assets and the CNS biomarker platform.

Biomarker Monetization The worldwide rights to Columbia's CNS biomarker software provide a tangible revenue path via licensing, software-as-a-service, or integration into CNS drug development programs for pharma, CROs, and research institutions seeking biomarker-enabled trials.

Psychedelic Focus The PCT patent on novel psilocin prodrugs and focus on neurological and psychiatric diseases position Terran to partner with psychedelic-focused investors and clinical programs for early-stage asset development, licensing, or joint ventures.

IP Advantage An active IP posture and history of collaboration with leading institutions create a defensible moat that can attract risk-aware partners seeking secure pipelines and rigorous diligence for co-development or licensing deals.

Lean Growth With a lean team and revenue in the lower end of the scale, Terran can accelerate growth by forming channel partnerships with CROs, CMOs, and universities to scale development and commercialization without significant in-house expansion.